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Is chronic breathlessness less recognised
and treated compared with chronic pain?
A case-based randomised controlled trial
To the Editor:
Chronic breathlessness is a major cause of suffering in chronic obstructive pulmonary disease (COPD) [1].
Despite the impact on patients’ daily lives, chronic breathlessness might be under-recognised and
under-treated. No previous study has explored physicians’ ability to identify chronic breathlessness in
relation to other chronic symptoms.
Chronic pain, in contrast to chronic breathlessness [2], is a well-recognised clinical syndrome [3].
Measurement and treatment of pain is standard of care in many settings and is considered a basic human
right [3]. It has been suggested that identification and optimal treatment of chronic breathlessness should
also be recognised as a basic right [4, 5].
Evidence-based symptomatic treatment for chronic breathlessness is available, including both
non-pharmacological and pharmacological interventions. The pharmacological treatment with the
strongest evidence is low-dose, oral extended-release morphine [6, 7]. Observational studies report that
physicians remain reluctant to prescribe opioids for relief of breathlessness in COPD patients [8–11].
A recent meta-analysis reported no evidence of clinically relevant respiratory adverse effects of low-dose
opioids for chronic breathlessness [12].
We aimed to test the hypotheses that compared with chronic pain, chronic breathlessness is less likely to
be recognised by physicians as needing symptomatic treatment and to receive treatment with opioids in
severe COPD. The secondary aim was to compare reasons for not treating patients with opioids between
chronic breathlessness and pain.
This was a double-blind, randomised (1:1), controlled, parallel-group, web-based trial using hypothetical
case scenarios. The study was approved by Lund University Research Ethics Committee (Dnr: 2015/596)
and prospectively registered with ClinicalTrials.gov (NCT02728674). All participants gave their informed
consent. Inclusion criteria were: licensed physician; treating patients with respiratory problems in clinical
practice; able to understand a case description in Swedish; not on the research team and not aware of the
study’s design or content; and no previous participation.
The case scenario related to a patient (59 years old, former smoker, optimally treated hypertension,
medication with paracetamol and nonsteroidal anti-inflammatory drug allergy) who was diagnosed with
severe COPD. The patient was optimally treated with triple inhalation therapy, vaccination against
Influenza and Pneumococcus spp. and individualised pulmonary rehabilitation according to current
guidelines [13]. At follow-up, the patient was said to be troubled by severe [“breathlessness” or “pain”]
that markedly restricted daily activities and that had remained unchanged for at least three months. The
case progressively revealed more information and questions on how the physician would manage the
patient. The participant had to answer each question in order to advance to the next page and would not
return to or change earlier responses.
The study endpoints were assessed in four stages.
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1) Need of further treatment (“How do you manage the patient now?”: “Additional diagnostic measures”;
“Additional treatment”; “Active watchful waiting with follow-up visit”; or “Has optimal treatment at
present, new contact if necessary”.)
2) If additional treatment, type of additional treatment (“What do you want to treat additionally in the
















































































FIGURE 1 Study design and main findings.
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3) If symptoms, which symptomatic treatment (“Which treatments would you offer?”: “Changed
inhalation therapy”; “Intensified rehabilitation training”; “Benzodiazepines”; “Opioid, e.g. morphine”; “Oral
steroid, e.g. prednisolone”; “Roflumilast (daxas)”; “Oxygen therapy”; “Theophylline”; or “Other”.)
4) If not opioids, reasons for not treating with opioids.
At the end of the survey, all participants were informed that the patient had breathlessness with an
intensity of 7 out of 10 and answered whether the described patient suffered from chronic breathlessness,
and on how often they prescribed opioids in their clinical practice for breathlessness and pain, respectively.
The endpoints were compared between groups using chi-squared tests and multivariable logistic regression
adjusted for physician seniority (resident or consultant) and present working specialty (internal medicine,
primary care, pulmonary medicine or other). Statistical significance was defined as a two-tailed p<0.025
due to two co-primary endpoints. Analyses were performed using Stata version 14.2 (StataCorp LP;
College Station, TX, USA). Given the observed proportions of 10% versus 30% for identifying the need for
further symptomatic treatment, a sample size of 114 participants (57 per group) was required to obtain at
least 80% power for the primary analysis.
From September 2016 to May 2017, a total of 134 physicians were randomised to a case with chronic
breathlessness (n=72) or chronic pain (n=62; figure 1). Characteristics of the groups were well balanced;
median age 42 years; 53% males; 52% worked in hospital and 46% in primary care; and the mean work
experience as a physician was 11 years. For chronic breathlessness, compared with chronic pain of similar
severity, significantly fewer physicians recognised the need for further treatment (10% versus 31%;
p=0.002), fewer offered symptomatic treatment (4% versus 24%; p <0.001); and markedly fewer offered
treatment with opioids (3% versus 23%; p<0.001); (figure 1).
Findings were similar in adjusted analyses; physicians were less likely to recognise the need for further
treatment (OR 0.23; 95% CI 0.08–0.64), offer symptomatic treatment (OR 0.11; 95% CI 0.03–0.43) and
treat with opioids (OR 0.11; 95% CI 0.02–0.51). Reasons for not treating with opioids differed markedly
for breathlessness compared with pain: insufficient knowledge on usage and dosage of opioids (51% versus
4%; p<0.001); lack of optimal treatment guidelines (36% versus 17%; p=0.024); opioids considered relevant
by physicians only in an end-of-life setting (31% versus 4%; p<0.001). However, the risk of serious adverse
events was perceived as similar between the symptoms. Almost all (n=129; 96%) physicians considered
that the patient suffered from chronic breathlessness. Fewer physicians prescribed opioids in their clinical
practice for chronic breathlessness than for chronic pain (18% versus 31%; p<0.001) and markedly more
physicians never prescribed opioids for breathlessness than pain (47% versus 17%; p<0.001).
This is the first randomised trial to evaluate potential under-recognition and under-treatment of chronic
breathlessness in COPD. We found that compared with chronic pain, chronic breathlessness was markedly
less likely to be recognised as needing symptomatic treatment and to receive treatment with opioids. The
present findings extend previous small qualitative [9, 10] and observational data [11].
Despite that the patient was “Limited by severe [“breathlessness” or “pain”] that markedly restricted daily
activities”, chronic breathlessness was less likely to be identified as requiring additional treatment. There are
several potential reasons for this finding. Chronic breathlessness is so common in severe respiratory disease
that it might simply be considered by physicians, patients and caregivers as inevitable and part of the
patient’s normal life. Another potential reason is that breathlessness, despite recommendations, is rarely
systematically assessed or followed-up in clinical practice [14]. The finding might also, at least partly, reflect
skepticism among physicians of the availability of effective treatment for chronic breathlessness whereas
pain might be considered more amenable to treatment. Main reasons for not treating with opioids were
insufficient knowledge on usage and dosage of opioids and lack of optimal treatment guidelines. However,
the risk of serious adverse events was perceived as similar between the symptoms.
A limitation of the study is that management decisions in clinical practice may differ from responses to a
theoretical hypothetical case scenario. However, the case scenario represented a patient category and
situation that is frequently encountered in the clinicians’ practice, and participants were carefully
instructed to answer in accordance with their usual management. The differences in symptom recognition
and management in this trial were independent of the physician’s working specialty and level of seniority.
For clinicians, this study highlights the need to identify symptoms and their impact more actively, and
especially for chronic breathlessness; to systematically measure symptoms in daily practice and to actively
consider evidence-based symptomatic treatment.
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